Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Ambiante Health & Wellness vs Metabolyz

Ambiante Health & Wellness
Graded #449

Lower grade

vs+4.600000000000001
Metabolyz
Graded #339

Higher grade

The verdict

Metabolyz takes it — 59.6/100 to 55/100.

Metabolyz grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Metabolyz is a nationwide GLP-1 telehealth platform offering three compounded programs — standard semaglutide, dual-agonist tirzepatide, and a microdose protocol for patients near goal weight or intolerant…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueEven
45
45
Dose & formulationEven
40
40
Clinical oversightMetabolyz +3
78
81
Labs & monitoringMetabolyz +10
53
63
FulfillmentMetabolyz +21
65
86
Contract termsEven
55
55
Ambiante Health & Wellness · left barMetabolyz · right bar

The numbers

MetricAmbiante Health & WellnessMetabolyz
WeighScore55/10059.6/100
GradeCC
Scorecard rank#449#339
SemaglutideNot disclosedNot disclosed
TirzepatideNot disclosedNot disclosed
CoverageCoverage not publishedAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only

Strengths

  • Compounded semaglutide and tirzepatide plus a low-dose GLP-1 "Longevity Microdose" option, all provider-guided
  • Concierge model: dedicated provider, direct secure messaging, provider-directed dosing, and structured check-ins
  • Every plan bundles compounded medication, provider care, and discreet direct delivery with no hidden fees
  • No charge if you are not approved; published support hours (Mon-Fri, 9am-5pm ET) by phone and email

Where it loses points

  • GLP-1 program pricing is not published on the site — quoted only after provider review, so cost is not comparable up front
  • Compounding pharmacy partners are not publicly named (a transparency gap for medication sourcing)
  • No brand-name Wegovy, Zepbound, Mounjaro, or Ozempic — compounded formulations only
  • State availability is not published; private-pay only, and the practice serves women, so it is not a fit for everyone
  • No LegitScript or PCAB accreditation displayed on the marketing site
Metabolyz

Graded #339 · C

Strengths

  • Three GLP-1 programs: standard semaglutide, dual-agonist tirzepatide, and a microdose protocol for near-goal or dose-sensitive patients
  • Nutrition, movement, and lifestyle coaching included in all programs at no extra charge
  • Medication compounded in licensed 503A/503B US pharmacies with temperature-controlled, unmarked direct-to-door delivery
  • Licensed provider supervision with direct messaging access and structured check-ins throughout
  • Telehealth across all 50 states; BMI 27+ eligibility (25+ with weight-related condition)

Where it loses points

  • Pricing is fully gated — not disclosed until after consultation, preventing upfront cost comparison
  • Compounded GLP-1 only — no brand-name options (Wegovy, Zepbound) available
  • No LegitScript certification or named medical leadership found on public-facing pages
  • Labs not mentioned as included — unclear whether baseline or follow-up bloodwork is offered
  • Newer brand with no external reviews, published outcomes data, or notable accreditations

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard